TITLE: Chronic Pain Treatment in Patients with Chronic Kidney Failure: Clinical Effectiveness, Cost-Effectiveness and Guidelines

DATE: 18 August 2010

RESEARCH QUESTIONS:

1. What is the clinical and cost-effectiveness of buprenorphine patch versus opioids for the management of chronic pain for adult patients with chronic kidney disease?
2. What is the clinical and cost-effectiveness of duloxetine versus venlafaxine for the management of chronic pain for adult patients with chronic kidney disease?
3. What is the clinical and cost-effectiveness of gabapentin versus pregabalin for the management of chronic pain for adult patients with chronic kidney disease?
4. What is the clinical and cost-effectiveness of Sativex for the management of chronic pain for adult patients with chronic kidney disease?
5. What are the evidence-based guidelines for the management of chronic pain for adults with chronic kidney disease?

METHODS:

A limited literature search was conducted on key health technology assessment resources, including PubMed, the Cochrane Library (Issue 8, 2010), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI (Health Devices Gold), EuroScan, international health technology agencies, and a focused Internet search. The search was limited to English language articles published between January 1, 2005 and August 13, 2010. Filters were applied to limit the retrieval to guidelines for research question five. No filters were applied to limit the retrieval by study type for the other questions. Internet links were provided, where available.
RESULTS:

HTIS reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, economic evaluations, and evidence-based guidelines.

No relevant literature was identified regarding the clinical or cost-effectiveness of buprenorphine versus opioids, duloxetine versus venlafaxine, gabapentin versus pregabalin, or Sativex for the management of chronic pain for adult patients with chronic kidney disease. No relevant evidence-based guidelines were identified for the management of chronic pain for adults with chronic kidney disease. Additional articles of potential interest can be found in the appendix.

Health technology assessments
No literature identified.

Systematic reviews and meta-analyses
No literature identified.

Randomized controlled trials
No literature identified.

Non-randomized studies
No literature identified.

Economic evaluations
No literature identified.

Guidelines and recommendations
No literature identified.

PREPARED BY:
Health Technology Inquiry Service
Email: htis@cadth.ca
Tel: 1-866-898-8439
APPENDIX – FURTHER INFORMATION:

Non-randomized studies – non-comparative


Clinical practice guidelines (methodology not stated)


Review articles


Additional references


